Structure of the C-terminal Domains of Merozoite Surface Protein-1 from Plasmodium knowlesi Reveals a Novel Histidine Binding Site*

Scott C. GarmanDagger §, William N. SimcokeDagger , Anthony W. Stowers||, and David N. GarbocziDagger §

From the Dagger  Structural Biology Section, Laboratory of Immunogenetics and  Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Rockville, Maryland 20852

Received for publication, October 18, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The protozoan parasite Plasmodium causes malaria, with hundreds of millions of cases recorded annually. Protection against malaria infection can be conferred by antibodies against merozoite surface protein (MSP)-1, making it an attractive vaccine candidate. Here we present the structure of the C-terminal domains of MSP-1 (known as MSP-119) from Plasmodium knowlesi. The structure reveals two tightly packed epidermal growth factor-like domains oriented head to tail. In domain 1, the molecule displays a histidine binding site formed primarily by a highly conserved tryptophan. The protein carries a pronounced overall negative charge primarily due to the large number of acidic groups in domain 2. To map protein binding surfaces on MSP-119, we have analyzed the crystal contacts in five different crystal environments, revealing that domain 1 is highly preferred in protein-protein interactions. A comparison of MSP-119 structures from P. knowlesi, P. cynomolgi, and P. falciparum shows that, although the overall protein folds are similar, the molecules show significant differences in charge distribution. We propose the histidine binding site in domain 1 as a target for inhibitors of protein binding to MSP-1, which might prevent invasion of the merozoite into red blood cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A necessary step in the life cycle of the malaria parasite is its entry into the red blood cell of a mammalian host. This process involves many surface proteins specifically expressed at the merozoite stage of the parasite, including merozoite surface protein (MSP)1-1 (also known as merozoite surface antigen-1 or MSA-1). MSP-1, a required component of the merozoite invasion machinery, associates noncovalently with other parasite proteins, including the C-terminal portion of MSP-6 (1). MSP-1 is synthesized as a 180-225-kDa polypeptide capable of binding sialic acid (2, 3). As a requirement for merozoite entry into a red cell, MSP-1 undergoes two processing steps, the first at merozoite release from an infected cell and the second during invasion of a red cell (4) (Fig. 1a). In the first processing step, the precursor polypeptide is cleaved into four chains (with apparent molecular masses of 83, 30, 38, and 42 kDa) held together by noncovalent contacts (4-6). In the second processing step, the 42-kDa segment (MSP-142) is cleaved into two fragments with apparent molecular masses of 33 kDa (MSP-133) and 19 kDa (MSP-119 or MSP-1inv) (4). MSP-133 sheds from the surface, whereas MSP-119 remains anchored to the merozoite membrane by a glycosylphosphatidylinositol tail attached to the C-terminal residue (7-10).

Because high antibody titer against the C-terminal region of MSP-1 protects against severe malaria, this molecule represents an attractive vaccine candidate (11-13). Antibodies against MSP-119 correlate with clinical immunity (14, 15); however, recombinant MSP-119 is poorly immunogenic, presumably due to poor processing of the highly disulfide-bonded protein (16, 17). Antibodies to the C-terminal region of MSP-1 fall into two categories: protective antibodies that inhibit merozoite invasion of red cells, and blocking antibodies that enhance invasion by interfering with the binding of protective antibodies. Protective antibodies include those that recognize the native conformation of MSP-119 (7, 18-20), those that block proteolytic processing of MSP-142 (21), and certain antibodies to the 83-kDa N-terminal fragment of intact MSP-1 (22). Blocking antibodies bind to the first domain of MSP-119, near the N terminus introduced by the processing of MSP-142 (22, 23).

The extremely stable MSP-119 contains two consecutive epidermal growth factor (EGF)-like domains, a small disulfide-rich fold also found in diverse proteins including Factor Xa (24), E-selectin (25), cyclooxygenase-2 (26), and integrin alpha Vbeta 3 (27). In MSP-1, disulfide bonds are integral to the correct folding of the molecule (20). Although the full-length MSP-1 is highly polymorphic, the C-terminal EGF-like domains in MSP-119 are much less so, and they represent a conserved segment of a variable molecule. MSP-119 shows high sequence identity across Plasmodium species: P. knowlesi MSP-119 shares 82% sequence identity with P. cynomolgi and 51% sequence identity with P. falciparum.

To better understand the process of invasion of the Plasmodium merozoite into a red blood cell, we have solved the structure of the C-terminal domains of MSP-1 from P. knowlesi by x-ray crystallography. We have refined the structure to an R-factor of 23.4% and R-free of 26.4% to 2.4 Å resolution (Table I). Our structure reveals features of MSP-1 novel to P. knowlesi and provides new insight into MSP-1 from other Plasmodium species. With four copies in the crystallographic asymmetric unit, we observe MSP-1 in four different environments, allowing us to infer novel properties of the molecule.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Crystallographic statistics


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression and Purification-- DNA encoding the C-terminal 92 amino acids of the of P. knowlesi (Malayan H strain) MSP-1 (GenBankTM accession code AAG24615) was inserted into the vector YEpRPEU-3 and expressed in the Saccharomyces cerevisiae VK1 cell line (36). The vector included an N-terminal yeast alpha -factor pre-pro secretory signal and a C-terminal hexahistidine tag. The plasmid is episomally maintained by supplying a functional HIS4 gene for the host VK1 cell line (his4). Protein expression is under control of the ADH2 promoter and induced by introducing ethanol as a carbon source during fermentation. The secreted protein product included 105 amino acids: 5 amino acids (E-A-E-A-S) from the cleaved mating factor, the 92 amino acids from MSP-1, and 8 amino acids (G-P-H6) from the affinity tag. The protein was purified using nickel affinity, ion exchange, and gel filtration chromatography.

Crystallization and X-ray Data Collection-- Purified MSP-119 protein was concentrated to 10 mg/ml for crystallization trials. Crystals were grown via vapor diffusion with a solution containing 30% polyethylene glycol 6000, 100 mM HEPES, pH 7.0. Crystals were transferred into the same solution supplemented with 20% glycerol before cooling to 100 K in a nitrogen stream. X-ray data were collected on a Rigaku RU-200 rotating anode generator equipped with nickel mirrors and a RAXIS 4 detector (Molecular Structure Corp., The Woodlands, TX). 180° of diffraction data were processed using DENZO (37), SCALEPACK (37), and TRUNCATE (38) to a resolution limit of 2.4 Å.

Phasing and Refinement-- Molecular replacement was performed with the AMoRe package (38) using coordinates from the C-terminal domains of MSP-1 from P. cynomolgi (29). The P. cynomolgi model was rotated and translated against the 8-4 Å P. knowlesi diffraction amplitudes, using correlation coefficients to rank solutions. Four successive objects were placed in the crystallographic asymmetric unit, whereas insertion of a fifth object failed to improve the correlation coefficient. Inspection of the packing showed no steric clashes in a unit cell with 49% solvent content. Rigid body refinement in the programs AMoRe (38) and Crystallography and NMR System (CNS) (39) was followed by model building in the program O (40). Residue numbering of the P. knowlesi structure corresponds to the mature secreted protein and begins at the first residue of the cleaved alpha  mating factor secretory signal. Refinement protocols in CNS included conjugate gradient minimization, simulated annealing, and temperature factor refinement. Models were built into simulated annealing composite omit maps calculated in CNS. Tight 4-fold noncrystallographic symmetry restraints (300 kcal/mol-Å2) were imposed on all atoms in the early stages of refinement and later relaxed for atoms that differ among the four copies in the asymmetric unit. Refinement steps were accepted only if they reduced the R-free (of a test set comprised of 860 reflections, 5% of the total, selected using resolution shells). The R-work and R-free are 23.4% and 26.4%, respectively, using all reflections to 2.4 Å.

Calculations-- Least squares superpositions were performed using the program LSQMAN (41) with a distance cutoff of 3.8 Å, and coordinate transformations were applied using the program MOLEMAN2 (41). Structural comparisons with the NMR structure of P. falciparum MSP-119 (28) use the most representative member of the ensemble. Electrostatic calculations include only the native MSP-119 sequence, without the secretory signal and purification epitope. Molecular figures were prepared using the programs MOLSCRIPT (42), BOBSCRIPT (43), and GRASP (44).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Overall Description of the Structure-- The C-terminal region of P. knowlesi MSP-1 contains two successive EGF-like domains packed together tightly and related by a rotation of ~170° (Fig. 1b). The molecule is roughly square-shaped, with dimensions of about 35 Å × 35 Å × 15 Å. The angle between domains 1 and 2 leads to close approach of the N terminus of domain 1 and the C terminus of domain 2. Thus, as domain 2 is anchored in the membrane by a glycosylphosphatidylinositol linkage attached to the C-terminal residue, the N-terminal residue of domain 1 (i.e. the cleavage site in MSP-142) also points toward the membrane, in an appropriate orientation for processing by proteases attached to the merozoite membrane (28).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   The structure of MSP-119 from P. knowlesi. a, the two proteolytic processing stages of MSP-1. In the first processing step, the 200-kDa precursor is cleaved into four pieces. In the second step, the 42-kDa C-terminal segment is cleaved into two fragments, MSP-133 and MSP-119. Segments are not to scale. b, the MSP-119 ribbon representation including disulfide bonds. In each domain, beta  strands 1-4 are shown as ribbons labeled beta 1-beta 4. Disulfide bonds connect random coil to beta 1, coil to beta 2, and beta 2 to beta 4. This front view, with domain 1 on the left and domain 2 on the right, is also shown in c and in Figs. 3 and 4. The non-native residues from the C-terminal purification epitope are colored gray. c, the alpha  carbons of the four molecules in the crystallographic asymmetric unit are shown superimposed. Chain A is yellow, chain B is green, chain C is blue, and chain D is red. The structures differ significantly only at the termini and loop 69-74.

Each EGF-like domain in P. knowlesi MSP-1 contains a segment of random coil followed by four antiparallel beta  strands (Fig. 1b). Typically, EGF-like domains contain six cysteines in three disulfide bonds with a connectivity of 1-3, 2-4, and 5-6. The MSP-1 EGF-like domains follow this paradigm, except that in domain 1, valine and tryptophan replace the middle (2-4) disulfide. The valine and tryptophan pack into the domain 1 hydrophobic core, in the same volume as the disulfide bond in canonical EGF-like domains.

The crystals of P. knowlesi MSP-119 contain four molecules in the asymmetric unit, revealing the protein in four different environments. The four molecules are highly similar, with r.m.s. deviations of 0.4-0.6 Å for 77-81 Calpha atoms, with differences primarily at the two termini and residues 69-74 on the loop between beta  strands 1 and 2 in domain 2 (Fig. 1c). This loop shows differences across the four molecules in the crystallographic asymmetric unit and also within one molecule (as reflected by high B factors). The flexibility in this loop and in the termini corresponds to the mobility seen in the NMR structure of the P. falciparum MSP-119 (28).

In P. knowlesi MSP-119, the extensive interface between the two domains buries 26 residues and 1090 Å2 of surface area. This produces a rigid interface with little variation in the interdomain angle among the four copies in the asymmetric unit (Fig. 1c). The residues in the interface are among the most conserved in the MSP-119 protein: 23 of 26 residues are identical between P. knowlesi and P. cynomolgi, with three conservative substitutions; and 14 of 26 residues are identical between P. knowlesi and P. falciparum, with seven conservative substitutions. The highly conserved domain 2 sequence Asn57-Asn58-Gly59-Gly60 packs in the interface between domains 1 and 2, forming a short stretch of left-handed helix in P. knowlesi and P. cynomolgi and a tight turn in P. falciparum. P. knowlesi domain 1 superimposes on domain 2 with an r.m.s. deviation of 1.2-1.6 Å for the four independent copies in the asymmetric unit (Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Comparison of MSP-119 structures

Histidine Binding Site-- In all four copies of MSP-119 in the crystallographic asymmetric unit, electron density appears in a shallow depression on the surface (Fig. 2a). In each copy, the density traces back to a histidine from the hexahistidine tag of a symmetry-related molecule. For each of the four bound histidines, the plane of the imidazole ring stacks roughly parallel to the plane of the indole ring of Trp34, and the carboxylic acid of Glu42 pairs with the bound (and presumably protonated) histidine. In the histidine-binding pocket, Trp34 forms the floor, and Glu33 and Arg35 form the walls (Fig. 2b). The hydrophobic tryptophan and the bound histidine appear in the middle of a region of negative electrostatic potential (Fig. 2c). Although the conformation of the C-terminal hexahistidine tail differs in the four copies in the asymmetric unit, one histidine from the tail fills a histidine-binding pocket of a symmetry-related molecule. In the four copies in the asymmetric unit, each histidine binding buries between 167 and 206 Å2 of accessible surface area. This same pocket can bind other positively charged moieties: in the crystal of MSP-119 from P. cynomolgi (29), a lysine from a symmetry-related molecule inserts into this pocket.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   The histidine binding site. a, a stereo diagram of a 2Fo-Fc composite omit map, contoured at 1.3sigma , in the vicinity of the histidine binding site of P. knowlesi MSP-119 molecule C. The electron density in red derives from a symmetry-related molecule. b, a ribbon representation of a portion of domain 1 with side chains shown for residues around the histidine binding site. Histidines from four symmetry-related molecules are shown, colored as described in Fig. 1b. Residues Glu33, Trp34, Arg35, and Glu42 define the walls of the pocket. c, a surface representation of the same region, colored by electrostatic potential. The surface potential ranges from -10 kT (red) to +10 kT (blue). Bonds from the superimposed histidines are shown, colored as described in b. In molecule D, only the imidazole ring of the histidine is modeled.

In all Plasmodium species except P. falciparum, domain 1 of MSP-119 lacks the middle disulfide bond found in canonical EGF-like domains. The replacement of a disulfide by a small residue (valine, isoleucine, or threonine) and a tryptophan produces a shelf on domain 1 capable of binding histidine. Tryptophan is the residue most commonly found buried in protein-protein interfaces (30) because burial of its large hydrophobic surface area yields thermodynamic gain.

Protein Binding Surfaces-- The analysis of crystal contacts can be used to map protein binding surfaces on a molecule to reveal potential biologically important surfaces on the molecule (31, 32). We searched crystal contacts in MSP-119 to identify the favored sites for binding to proteins. Combining the four copies of P. knowlesi MSP-119 in the crystallographic asymmetric unit with the one copy of P. cynomolgi MSP-119 (29), we have observations of MSP-119 in five different crystal environments. We counted the number of times each residue participates in crystal contacts and mapped that number onto the surface of the protein (Fig. 3a). The P. knowlesi and P. cynomolgi crystal contacts correlate: of the 9 residues involved in crystal contacts in all four P. knowlesi copies, 7 make contacts in the P. cynomolgi crystals as well. The seven residues (Ile14, Asp15, Leu28, Trp34, Glu42, Ala50, and Ser51) participate in crystal contacts in all five crystal packing environments. All of these except Ser51 are conserved between P. knowlesi and P. cynomolgi, suggesting protein binding sites conserved across species. All of these except Leu28 differ between P. knowlesi and P. falciparum, resulting in distinctly shaped MSP-119 surfaces across these species.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   MSP-119 in crystal contacts and across species. a, the P. knowlesi MSP-119 molecular surface is shown, colored by the number of crystal contacts each residue makes, using the four molecules in the P. knowlesi asymmetric unit and the one molecule in the P. cynomolgi asymmetric unit. The surface has a color gradient from 0 (white; no contacts in any of the five molecules) to 5 (blue; contacts in each of the five molecules) crystal contacts/residue. The histidine binding site is circled in red. b, alpha  carbon traces of MSP-119 from P. knowlesi, P. cynomolgi, and P. falciparum are superimposed. The four copies of P. knowlesi MSP-119 are colored yellow, green, blue, and red; the P. cynomolgi MSP-119 is colored magenta; and the P. falciparum MSP-119 NMR structure is colored white. Non-native residues from the purification epitope of P. knowlesi are included at the bottom of domain 2.

The crystal contacts show that MSP-119 domain 1 is highly favored for binding protein (Fig. 3a). Trp34, the floor of the histidine binding site in the center of domain 1, falls in an ideal position to participate in protein-protein interactions on the surface of the merozoite. In P. falciparum MSP-119, domain 1 has been shown to be the binding site of monoclonal antibody G17.12 (33).

Comparison across Species-- The high level of sequence identity in MSP-119 across Plasmodium species results in highly similar three-dimensional structures of the molecule (Figs. 3b and 4a). The P. cynomolgi MSP-119 superimposes on the P. knowlesi structure with an r.m.s. deviation of 1.3 Å for 78 Calpha atoms, whereas the P. falciparum structure superimposes on the P. knowlesi structure with an r.m.s. deviation of 1.7 Å for 65 Calpha atoms (Table II). A superposition of the four P. knowlesi MSP-119 molecules with the P. cynomolgi and P. falciparum homologues reveals that the differences occur primarily at the termini and in the 69-74 loop, the same loop that shows variability among the four molecules in the P. knowlesi crystal.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 4.   Electrostatic potential and hydrophobicity. a, the amino acid sequences from the crystals of MSP-119 from P. knowlesi, P. cynomolgi, and P. falciparum. Cysteines are highlighted in yellow. b-d, surface representations of MSP-119 from three Plasmodium species are shown, colored by electrostatic potential (left) and hydrophobicity (right). Molecules are shown in two views 180° apart. Electrostatic potentials contoured from -10 kT (red) to +10 kT (blue) are plotted onto the molecular surface of MSP-119 from P. knowlesi, P. cynomolgi, and P. falciparum, respectively. Hydrophobicity values calculated from modified solvent transfer experiments (45) are contoured from -2 kcal/mol (most hydrophobic, in yellow) to 2 kcal/mol (hydrophilic, in green). The hydrophobic patches found on the surface tend to be from exposed portions of residues forming the interface between domains 1 and 2.

MSP-119 from P. knowlesi exhibits a striking charge distribution (Fig. 4b). The molecule carries a pronounced negative potential, with an overall charge of -7 in the 92 residues of the two domains. There are no buried ion pairs in P. knowlesi MSP-119; rather, all charged residues are surface-accessible. The overall charge is species-specific because the equivalent segments of MSP-1 from P. cynomolgi and P. falciparum have overall charges of -4 and -2, respectively (Fig. 4, c and d). In P. knowlesi MSP-119, the negative charge is concentrated in domain 2 (with an overall charge of -7), whereas domain 1 is neutrally charged overall. The acidic regions in domain 1 cluster near the histidine binding site.

Hydrophobicity maps of the three Plasmodium MSP-119 structures show a patch of nonpolar residues along the interface between the two domains (Fig. 4, b-d). Of the 26 residues contributing to the interface, 15 are hydrophobic, and 3 are cysteines in disulfide bonds. Because the molecule is only 15 Å thick, some hydrophobic residues in the interdomain interface (including Tyr25, Tyr27, Leu37, Leu38, and Phe88) remain partially solvent-accessible. Surprisingly, the large patch of hydrophobic residues on the back surface is among the least active surfaces in protein binding, as judged by the crystal contact analysis (Fig. 3a).

The arrangement of charged and hydrophobic residues on MSP-119 may maintain specificity of the interactions between MSP-119 and its binding partners such as the other MSP-1 fragments and MSP-6. Complementary changes between residues in MSP-119 and its binding partners may allow evolution of the MSP-119 protein surface.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The region around Trp34 appears to be a site on P. knowlesi MSP-119 well suited for protein-protein interactions. First, all EGF-like domain structures contain at least three pairs of disulfide bonds, with one exception: the first domain of MSP-119. Of the 40 independent EGF/laminin-like domain structures currently in the Protein Data Bank (34), only Plasmodium MSP-119 has lost one of its three canonical disulfide bonds. The loss of a structurally important and highly conserved disulfide bond is most likely due to a functional requirement. Second, all of the Plasmodium species (except P. falciparum) contain a tryptophan in domain 1 of MSP-119 in place of the canonical cysteine. The disulfide is replaced with a tryptophan and a smaller residue; whereas the smaller residue may become a valine, isoleucine, or threonine, the other member of the pair is always tryptophan, suggesting functional selection. Third, tryptophan is the residue most commonly found in protein-protein interfaces (30), so the replacement of a strictly conserved disulfide-forming cysteine with a tryptophan suggests the evolution of a protein binding site. Fourth, there are no instances of crystals of MSP-119 with an empty histidine-binding pocket. In all five independent crystallographic environments, a histidine or lysine is found stacked above the tryptophan ring. This pocket fills when the concentration of nearby protein becomes sufficiently high. Fifth, the crystal contact map of MSP-119 indicates that the tryptophan and nearby regions in domain 1 are very active in participating in protein-protein interactions.

The sequence differences between P. falciparum and the other Plasmodium species represent divergent evolution from a common precursor, but it is unclear whether P. falciparum has lost a binding site or the other Plasmodium species have evolved new functionality. Alternatively, the difference between P. falciparum and the other Plasmodia may be due to the strong bias against tryptophan in P. falciparum (35). The virulent P. falciparum displays somewhat different disease pathology compared with the other Plasmodium species; perhaps the differences in MSP-119 proteins are related to the differences in disease severity. For example, P. falciparum invades a broader spectrum of red blood cells and reaches higher levels of parasitemia compared with other malaria species, potentially due to loss of receptor specificity in P. falciparum. Some of this specificity may be conferred by the MSP-1 protein during red blood cell invasion. Although P. falciparum lacks the tryptophan defining the floor of the binding pocket, all the other species of Plasmodium have this tryptophan, which generates a site for binding histidine. We propose the use of this histidine binding site as a target for the design of compounds that bind, for example, P. vivax MSP-1. From such a scaffold compound, new inhibitors that protect against merozoite invasion of a red blood cell might be developed.

Our structure reveals a new feature of the MSP-119 molecule, a histidine-binding pocket in domain 1. Because antibodies that protect against malarial infections often bind specifically to domain 1, this new property of the molecule might be used to engineer tighter binding and thus more protective antibodies. Alternatively, this histidine-binding pocket might be used to interfere with the binding of blocking antibodies. For example, a small molecule inhibitor containing an imidazole scaffold may be designed to overlap with the footprint of blocking antibodies and thus disrupt the binding of blocking antibodies. The specific disruption of MSP-119 blocking antibodies without perturbation of protective antibodies would greatly enhance the immune response against the malaria parasite.

    ACKNOWLEDGEMENTS

We thank T. Allison and the other members of the Structural Biology Section for discussions.

    FOOTNOTES

* This work was supported by the Intramural Program of the NIAID.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1N1I) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

§ To whom correspondence may be addressed: Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, 12441 Parklawn Dr., Rockville, MD 20852. E-mail: garman{at}alpha.niaid.nih.gov (for S. C. G.) or garboczi{at}nih.gov (for D. N. G.).

|| Present address: CSL Limited, 45 Poplar Rd., Parkville, Victoria 3052, Australia.

Published, JBC Papers in Press, December 19, 2002, DOI 10.1074/jbc.M210716200

    ABBREVIATIONS

The abbreviations used are: MSP, merozoite surface protein; EGF, epidermal growth factor; r.m.s., root mean square.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Trucco, C., Fernandez-Reyes, D., Howell, S., Stafford, W. H., Scott-Finnigan, T. J., Grainger, M., Ogun, S. A., Taylor, W. R., and Holder, A. A. (2001) Mol. Biochem. Parasitol. 112, 91-101[CrossRef][Medline] [Order article via Infotrieve]
2. Perkins, M. E., and Rocco, L. J. (1988) J. Immunol. 141, 3190-3196[Abstract/Free Full Text]
3. Su, S., Sanadi, A. R., Ifon, E., and Davidson, E. A. (1993) J. Immunol. 151, 2309-2317[Abstract/Free Full Text]
4. Holder, A. A., Blackman, M. J., Burghaus, P. A., Chappel, J. A., Ling, I. T., McCallum-Deighton, N., and Shai, S. (1992) Mem. Inst. Oswaldo Cruz 87 Suppl. 3, 37-42[Medline] [Order article via Infotrieve]
5. Holder, A. A., Sandhu, J. S., Hillman, Y., Davey, L. S., Nicholls, S. C., Cooper, H., and Lockyer, M. J. (1987) Parasitology 94, 199-208[Medline] [Order article via Infotrieve]
6. McBride, J. S., and Heidrich, H. G. (1987) Mol. Biochem. Parasitol. 23, 71-84[CrossRef][Medline] [Order article via Infotrieve]
7. Blackman, M. J., Heidrich, H. G., Donachie, S., McBride, J. S., and Holder, A. A. (1990) J. Exp. Med. 172, 379-382[Abstract]
8. Blackman, M. J., and Holder, A. A. (1992) Mol. Biochem. Parasitol. 50, 307-315[CrossRef][Medline] [Order article via Infotrieve]
9. Blackman, M. J., Ling, I. T., Nicholls, S. C., and Holder, A. A. (1991) Mol. Biochem. Parasitol. 49, 29-33[CrossRef][Medline] [Order article via Infotrieve]
10. Blackman, M. J., Whittle, H., and Holder, A. A. (1991) Mol. Biochem. Parasitol. 49, 35-44[CrossRef][Medline] [Order article via Infotrieve]
11. al-Yaman, F., Genton, B., Kramer, K. J., Chang, S. P., Hui, G. S., Baisor, M., and Alpers, M. P. (1996) Am. J. Trop. Med. Hyg. 54, 443-448[Medline] [Order article via Infotrieve]
12. Egan, A. F., Morris, J., Barnish, G., Allen, S., Greenwood, B. M., Kaslow, D. C., Holder, A. A., and Riley, E. M. (1996) J. Infect. Dis. 173, 765-769[Medline] [Order article via Infotrieve]
13. Riley, E. M., Allen, S. J., Wheeler, J. G., Blackman, M. J., Bennett, S., Takacs, B., Schonfeld, H. J., Holder, A. A., and Greenwood, B. M. (1992) Parasite Immunol. (Oxf.) 14, 321-337
14. Shi, Y. P., Sayed, U., Qari, S. H., Roberts, J. M., Udhayakumar, V., Oloo, A. J., Hawley, W. A., Kaslow, D. C., Nahlen, B. L., and Lal, A. A. (1996) Infect. Immun. 64, 2716-2723[Abstract]
15. O'Donnell, R. A., de Koning-Ward, T. F., Burt, R. A., Bockarie, M., Reeder, J. C., Cowman, A. F., and Crabb, B. S. (2001) J. Exp. Med. 193, 1403-1412[Abstract/Free Full Text]
16. Egan, A. F., Chappel, J. A., Burghaus, P. A., Morris, J. S., McBride, J. S., Holder, A. A., Kaslow, D. C., and Riley, E. M. (1995) Infect. Immun. 63, 456-466[Abstract]
17. Egan, A., Waterfall, M., Pinder, M., Holder, A., and Riley, E. (1997) Infect. Immun. 65, 3024-3031[Abstract]
18. Chang, S. P., Gibson, H. L., Lee-Ng, C. T., Barr, P. J., and Hui, G. S. (1992) J. Immunol. 149, 548-555[Abstract/Free Full Text]
19. Hui, G. S., Chang, S. P., Gibson, H., Hashimoto, A., Hashiro, C., Barr, P. J., and Kotani, S. (1991) J. Immunol. 147, 3935-3941[Abstract/Free Full Text]
20. Locher, C. P., and Tam, L. Q. (1993) Vaccine 11, 1119-1123[Medline] [Order article via Infotrieve]
21. Blackman, M. J., Scott-Finnigan, T. J., Shai, S., and Holder, A. A. (1994) J. Exp. Med. 180, 389-393[Abstract]
22. Guevara Patino, J. A., Holder, A. A., McBride, J. S., and Blackman, M. J. (1997) J. Exp. Med. 186, 1689-1699[Abstract/Free Full Text]
23. Chappel, J. A., Egan, A. F., Riley, E. M., Druilhe, P., and Holder, A. A. (1994) Infect. Immun. 62, 4488-4494[Abstract]
24. Padmanabhan, K., Padmanabhan, K. P., Tulinsky, A., Park, C. H., Bode, W., Huber, R., Blankenship, D. T., Cardin, A. D., and Kisiel, W. (1993) J. Mol. Biol. 232, 947-966[CrossRef][Medline] [Order article via Infotrieve]
25. Graves, B. J., Crowther, R. L., Chandran, C., Rumberger, J. M., Li, S., Huang, K. S., Presky, D. H., Familletti, P. C., Wolitzky, B. A., and Burns, D. K. (1994) Nature 367, 532-538[CrossRef][Medline] [Order article via Infotrieve]
26. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., Miyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C., and Stallings, W. C. (1996) Nature 384, 644-648[CrossRef][Medline] [Order article via Infotrieve]
27. Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Science 294, 339-345[Abstract/Free Full Text]
28. Morgan, W. D., Birdsall, B., Frenkiel, T. A., Gradwell, M. G., Burghaus, P. A., Syed, S. E., Uthaipibull, C., Holder, A. A., and Feeney, J. (1999) J. Mol. Biol. 289, 113-122[CrossRef][Medline] [Order article via Infotrieve]
29. Chitarra, V., Holm, I., Bentley, G. A., Petres, S., and Longacre, S. (1999) Mol. Cell 3, 457-464[Medline] [Order article via Infotrieve]
30. Glaser, F., Steinberg, D. M., Vakser, I. A., and Ben-Tal, N. (2001) Proteins 43, 89-102[CrossRef][Medline] [Order article via Infotrieve]
31. Crosio, M. P., Janin, J., and Jullien, M. (1992) J. Mol. Biol. 228, 243-251[Medline] [Order article via Infotrieve]
32. Garman, S. C., Sechi, S., Kinet, J. P., and Jardetzky, T. S. (2001) J. Mol. Biol. 311, 1049-1062[CrossRef][Medline] [Order article via Infotrieve]
33. Pizarro, J. C., Chitarra, V., Calvet, C., Verger, D., and Bentley, G. A. (2002) Acta Crystallogr. Sect. D Biol. Crystallogr. 58, 1246-1248[CrossRef][Medline] [Order article via Infotrieve]
34. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) Nucleic Acids Res. 28, 235-242[Abstract/Free Full Text]
35. Tchavtchitch, M., Fischer, K., Huestis, R., and Saul, A. (2001) Mol. Biochem. Parasitol. 118, 211-222[CrossRef][Medline] [Order article via Infotrieve]
36. Stowers, A. W., Keister, D. B., Muratova, O., and Kaslow, D. C. (2000) Infect. Immun. 68, 5530-5538[Abstract/Free Full Text]
37. Otwinowski, Z., and Minor, W. (1997) in Methods in Enzymology: Macromolecular Crystallography, Part A (Carter, C. W. , and Sweet, R. M., eds), Vol. 276 , pp. 307-326, Academic Press, New York
38. Collaborative Computational Project, Number 4.. (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760-763[CrossRef][Medline] [Order article via Infotrieve]
39. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
40. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta. Crystallogr. Sect. A 47, 110-119[CrossRef][Medline] [Order article via Infotrieve]
41. Kleywegt, G. J., and Read, R. J. (1997) Structure 5, 1557-1569[Medline] [Order article via Infotrieve]
42. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
43. Esnouf, R. M. (1997) J. Mol. Graph. Model. 15, 132-134[CrossRef][Medline] [Order article via Infotrieve]
44. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins 11, 281-296[Medline] [Order article via Infotrieve]
45. Roseman, M. A. (1988) J. Mol. Biol. 200, 513-522[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.